Skip to main content
. 2019 Oct 1;8(16):6967–6976. doi: 10.1002/cam4.2593

Figure 2.

Figure 2

Progression‐free survival (A) and overall survival (B) according to neutrophil‐to‐lymphocyte ratio and myosteatosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy